(Q87446725)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

editorial

0 references

title

Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

2

Gregory A Poland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Tewodros Mamo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

number of pages

3

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

6609-6611

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery?

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Alum adjuvant: some of the tricks of the oldest adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

New adjuvants for human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

The path to a successful vaccine adjuvant--'the long and winding road'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Recent advances with liposomes as pharmaceutical carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

On firm ground: IP protection of therapeutic nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Impact of albumin on drug delivery--new applications on the horizon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Proof of concept for next-generation nanoparticle drugs in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Programming the magnitude and persistence of antibody responses with innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Peptide-based subunit nanovaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

The impact of nanoparticle ligand density on dendritic-cell targeted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Design opportunities for actively targeted nanoparticle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Decreased lung carcinoma cell density on select polymer nanometer surface features for lung replacement therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Nanotechnology and the transdermal route: A state of the art review and critical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

The golden age: gold nanoparticles for biomedicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Highly controlled synthesis of nanometric gold particles by citrate reduction using the short mixing, heating and quenching times achievable in a microfluidic device

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.023

10.1016/J.VACCINE.2012.08.023

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23067445%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference